Suzhou Ribo Life Science Co., Ltd. was established in 2007 by among others two distinguished Swedish/Chinese RNA-researchers in China and is today a clinical stage biotech company specialized on the development of RNA interference (RNAi) technologies and oligonucleotide therapeutics. As the major pioneer and leader in the RNAi technology and oligonucleotide therapeutics industry in China, Suzhou Ribo Life Science Co., Ltd. has vertically integrated its cutting-edge RNAi technologies including GalNAc liver-targeting delivery technology and established the oligonucleotide drug development platform by years of efforts. Suzhou Ribo Life Science Co., Ltd. has built up a highly capable R&D, manufacturing, and operational management team with extensive years of experiences in the pharmaceutical industry. The company is headquartered in Kunshan, Jiangsu Province, China, and has a R&D center in Beijing.
Specific efforts will be directed to building innovative capacities to conduct clinical trials and developing siRNA drugs for disease indications such as liver diseases, cardiovascular and metabolic diseases, as well as orphan diseases to address real unmet medical needs.
Please visit Suzhou Ribo Life Science Co., Ltd. for the current pipeline of the parent company.
Ribocure will be expanding heavily in Sweden and looking for new talents to join, and academic associations as well as small and large enterprise partners to collaborate with, with the joint goal of developing highly differentiated and innovative oligonucleotide therapeutics to help patients in need.